Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization

Vaccine

Volumn 25, Issue 27, 2007, Pages 5041-5045

  Tandan, J B ^a   Ohrr, Heechoul ^b   Sohn, Young Mo ^b   Yoksan, Sutee ^c   Ji, Min ^d   Nam, Chung Mo ^b   Halstead, Scott B ^e  

^a Department of Nursing Dhaulagiri Prabhidhik Shikshya Pratisthan   (Nepal)

^b Yonsei University College of Medicine   (South Korea)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Glovax Co Ltd   (South Korea)

^e Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Flavivirus; Japanese encephalitis; Vaccine

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; SA 14 14 2; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; EPIDEMIC ENCEPHALITIS; EXPOSURE; FEMALE; HOSPITALIZATION; HUMAN; IMMUNIZATION; MALE; NEPAL; PREVALENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; ENCEPHALITIS, JAPANESE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; JAPANESE ENCEPHALITIS VACCINES; MALE; NEPAL; PLAQUE ASSAY; VACCINES, ATTENUATED;

EID: 34250028171     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.052     Document Type: Article

References (15)

1. Ministry of Health, Epidemiology and Disease Control Division, Nepal, JE Cases; 2004.
2. Bista M.B., and Shrestha J.M. Epidemiological situation of Japanese encephalitis in Nepal. J Nep Med Assoc 44 (2005) 51-56
3. Bista M.B., Banerjee M.K., Shin S.H., Tandan J.B., Kim M.H., Sohn Y.M., et al. Efficacy of single dose SA 14-14-2 vaccine against Japanese encephalitis: a case-control study. Lancet 358 (2001) 791-795
4. Ohrr H., Tandan J.B., Sohn Y.M., Shin S.H., Pradhan D.P., and Halstead S.B. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366 (2005) 1375-1378
5. Russell P.K., Nisalak A., Sukhavachana P., and Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99 (1967) 285-290
6. Chen W.R., Tesh R.B., and Rico-Hesse R. Genetic variation of Japanese encephalitis in nature. J Gen Virol 71 (1990) 2915-2922
7. Innis B.L., Nisalak A., Nimmannitya S., Kusalerdehariya S., Chongswasdi V., Suntayakorn S., et al. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40 (1989) 127-418
8. Orenstein W.A., Bernier R.H., Dondero T.J., Hinman A.F., Marks J.S., and Bart K.J. Field evaluation of vaccine efficacy. Bull World Health Organ 63 (1985) 1055-1068
9. Rodrigues L.C., and Smith P.G. Use of the case-control approaches in vaccine evaluation: efficacy and adverse effects. Epidemiol Rev 21 (1999) 56-72
10. In: Rothman K.J., and Greenland S. (Eds). Modern epidemiology. 2nd ed. (1998), Lippincott-Raven, Philadelphia
11. Hirji K.F., Mehta C.R., and Patel N.R. Exact inference for matched case-control studies. Biometrics 44 (1988) 803-814
12. Ministry of Health, Epidemiology and Disease Control Division, Nepal. Annual Report 2002 and 2003.
13. Bheri Zonal Hospital and Bardiya Hospital JE Case Record Section Report 2004.
14. WHO position paper. Japanese encephalitis vaccine. Wkly Epidemiol Rec 2006;81:331-40.
15. State investigation reports of Adverse Events following Immunization (AEFI) after Japanese encephalitis (JE) vaccination in high risk districts covering 4 States of the country. Reported in JE flash: http://www.path.org/vaccineresources/files/JEflash_14Nov06.